.AstraZeneca has shared a very early examine the performance of its own in-house antibody-drug conju...
.After declaring a stage 3 launch based on good midstage results, iTeos and GSK are actually finally...
.The FDA should be even more available as well as collective to let loose a surge in approvals of un...
.It's an unusually occupied Friday for biotech IPOs, along with Zenas BioPharma, MBX and also Bicara...
.Atea Pharmaceuticals' antiviral has failed another COVID-19 trial, yet the biotech still stores out...
.Neurocrine Biosciences' schizophrenia plan pivot has failed. The biotech was incapable to replicate...
.Sanofi has created an overdue access to the radioligand party, spending one hundred thousand euros ...
.After F2G's very first try to acquire a new class of antifungal to market was thwarted due to the F...
.Moderna has sworn to cut R&D costs through $1.1 billion by 2027. The decision to retract the bud...
.Simply four months after Sanofi bet $80 million in ahead of time cash on Pivot Therapeutics' losmap...